Product Code: LI_172021 / A01691
The global nanomedicine market was valued at $171,695.33 million in 2020, and is projected to reach $393,046.52 million by 2030, registering a CAGR of 9.2% from 2021 to 2030.
Nanomedicine is a branch of medicine that uses tools and knowledge of nanotechnology for prevention and treatment of different diseases. Nanomedicines are multifunctional drugs with programmable properties that find applications in monitoring, construction, repair, and control of biological systems at the molecular level using nanodevices and nanoparticles. They have the potential to revolutionize the current scenario of detection of disease, its treatment, and diagnosis methods.
Emerging innovative technologies for drug delivery, advantages of nanomedicine in various healthcare applications, and rise in government support and funding drive growth of the market. Moreover, growth in need for safe and cost-effective therapies also contribute toward growth of the market. However, long approval process and risks associated with nanomedicines (environmental impact) are expected to hinder the market growth. Conversely, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are expected to offer lucrative opportunities for market expansion during the forecast period.
The nanomedicine market is segmented on the basis of modality, application, indication and region. On the basis of modality, the market is segmented into diagnostics and treatment. On the basis of application, the market is segmented into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. On the basis of indication, the market is segmented into clinical oncology, infectious diseases, clinical cardiology, orthopedics, neurology, urology, ophthalmology, immunology and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the nanomedicine market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
- By MODALITY
- By APPLICATION
- Drug Delivery
- Diagnostic Imaging
- Vaccines
- Regenerative Medicine
- Implants
- Others
- By INDICATION
- Clinical Oncology
- Infectious Diseases
- Clinical Cardiology
- Orthopedics
- Neurology
- Urology
- Ophthalmology
- Immunology
- Others
- By REGION
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- Abbott Laboratories
- DiaSorin S.p.A.
- General Electric Company
- Invitae Corporation
- Johnson & Johnson
- Leadient BioSciences Inc.
- Mallinckrodt plc
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceuticals Ltd.
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report Description
- 1.2.Key Market Segments
- 1.3.Key Benefits
- 1.4.Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:MARKET LANDSCAPE
- 3.1.Market Definition and Scope
- 3.2.Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3.Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4.Market Share Analysis/Top Player Positioning
- 3.4.1. Market Share Analysis/Top Player Positioning 2020
- 3.5.Market Dynamics
- 3.5.1. Drivers
- 3.5.2. Restraints
- 3.5.3. Opportunities
- 3.6.COVID-19 Impact Analysis
CHAPTER 4:NANOMEDICINE MARKET, BY APPLICATION
- 4.1.Market Overview
- 4.1.1Market Size and Forecast, By Application
- 4.2. Drug Delivery
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Diagnostic Imaging
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Regenerative Medicine
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- 4.5. Implants
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
- 4.6. Vaccines
- 4.6.1. Key Market Trends, Growth Factors and Opportunities
- 4.6.2. Market Size and Forecast, By Region
- 4.6.3. Market Share Analysis, By Country
- 4.7. Others
- 4.7.1. Key Market Trends, Growth Factors and Opportunities
- 4.7.2. Market Size and Forecast, By Region
- 4.7.3. Market Share Analysis, By Country
CHAPTER 5:NANOMEDICINE MARKET, BY INDICATION
- 5.1.Market Overview
- 5.1.1Market Size and Forecast, By Indication
- 5.2. Clinical Oncology
- 5.2.1. Market Size and Forecast, By Region
- 5.2.2. Market Share Analysis, By Country
- 5.3. Infectious Diseases
- 5.3.1. Market Size and Forecast, By Region
- 5.3.2. Market Share Analysis, By Country
- 5.4. Clinical Cardiology
- 5.4.1. Market Size and Forecast, By Region
- 5.4.2. Market Share Analysis, By Country
- 5.5. Orthopedics
- 5.5.1. Market Size and Forecast, By Region
- 5.5.2. Market Share Analysis, By Country
- 5.6. Neurology
- 5.6.1. Market Size and Forecast, By Region
- 5.6.2. Market Share Analysis, By Country
- 5.7. Urology
- 5.7.1. Market Size and Forecast, By Region
- 5.7.2. Market Share Analysis, By Country
- 5.8. Ophthalmology
- 5.8.1. Market Size and Forecast, By Region
- 5.8.2. Market Share Analysis, By Country
- 5.9. Immunology
- 5.9.1. Market Size and Forecast, By Region
- 5.9.2. Market Share Analysis, By Country
- 5.10. Others
- 5.10.1. Market Size and Forecast, By Region
- 5.10.2. Market Share Analysis, By Country
CHAPTER 6:NANOMEDICINE MARKET, BY MODALITY
- 6.1.Market Overview
- 6.1.1.Market Size and Forecast, By Modality
- 6.2. Treatments
- 6.2.1. Market Size and Forecast, By Region
- 6.2.2. Market Share Analysis, By Country
- 6.3. Diagnostics
- 6.3.1. Market Size and Forecast, By Region
- 6.3.2. Market Share Analysis, By Country
CHAPTER 7:NANOMEDICINE MARKET, BY REGION
- 7.1.Market Overview
- 7.1.1Market Size and Forecast, By Region
- 7.2.North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Application
- 7.2.3. Market Size and Forecast, By Indication
- 7.2.4. Market Size and Forecast, By Modality
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. United States Nanomedicine Market
- 7.2.6.1. Market Size and Forecast, By Application
- 7.2.6.2. Market Size and Forecast, By Indication
- 7.2.6.3. Market Size and Forecast, By Modality
- 7.2.7. Canada Nanomedicine Market
- 7.2.7.1. Market Size and Forecast, By Application
- 7.2.7.2. Market Size and Forecast, By Indication
- 7.2.7.3. Market Size and Forecast, By Modality
- 7.2.8. Mexico Nanomedicine Market
- 7.2.8.1. Market Size and Forecast, By Application
- 7.2.8.2. Market Size and Forecast, By Indication
- 7.2.8.3. Market Size and Forecast, By Modality
- 7.3.Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Application
- 7.3.3. Market Size and Forecast, By Indication
- 7.3.4. Market Size and Forecast, By Modality
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Nanomedicine Market
- 7.3.6.1. Market Size and Forecast, By Application
- 7.3.6.2. Market Size and Forecast, By Indication
- 7.3.6.3. Market Size and Forecast, By Modality
- 7.3.7. France Nanomedicine Market
- 7.3.7.1. Market Size and Forecast, By Application
- 7.3.7.2. Market Size and Forecast, By Indication
- 7.3.7.3. Market Size and Forecast, By Modality
- 7.3.8. Uk Nanomedicine Market
- 7.3.8.1. Market Size and Forecast, By Application
- 7.3.8.2. Market Size and Forecast, By Indication
- 7.3.8.3. Market Size and Forecast, By Modality
- 7.3.9. Italy Nanomedicine Market
- 7.3.9.1. Market Size and Forecast, By Application
- 7.3.9.2. Market Size and Forecast, By Indication
- 7.3.9.3. Market Size and Forecast, By Modality
- 7.3.10. Spain Nanomedicine Market
- 7.3.10.1. Market Size and Forecast, By Application
- 7.3.10.2. Market Size and Forecast, By Indication
- 7.3.10.3. Market Size and Forecast, By Modality
- 7.3.11. Rest Of Europe Nanomedicine Market
- 7.3.11.1. Market Size and Forecast, By Application
- 7.3.11.2. Market Size and Forecast, By Indication
- 7.3.11.3. Market Size and Forecast, By Modality
- 7.4.Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Application
- 7.4.3. Market Size and Forecast, By Indication
- 7.4.4. Market Size and Forecast, By Modality
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Nanomedicine Market
- 7.4.6.1. Market Size and Forecast, By Application
- 7.4.6.2. Market Size and Forecast, By Indication
- 7.4.6.3. Market Size and Forecast, By Modality
- 7.4.7. China Nanomedicine Market
- 7.4.7.1. Market Size and Forecast, By Application
- 7.4.7.2. Market Size and Forecast, By Indication
- 7.4.7.3. Market Size and Forecast, By Modality
- 7.4.8. Australia Nanomedicine Market
- 7.4.8.1. Market Size and Forecast, By Application
- 7.4.8.2. Market Size and Forecast, By Indication
- 7.4.8.3. Market Size and Forecast, By Modality
- 7.4.9. India Nanomedicine Market
- 7.4.9.1. Market Size and Forecast, By Application
- 7.4.9.2. Market Size and Forecast, By Indication
- 7.4.9.3. Market Size and Forecast, By Modality
- 7.4.10. South Korea Nanomedicine Market
- 7.4.10.1. Market Size and Forecast, By Application
- 7.4.10.2. Market Size and Forecast, By Indication
- 7.4.10.3. Market Size and Forecast, By Modality
- 7.4.11. Rest Of Asia-pacific Nanomedicine Market
- 7.4.11.1. Market Size and Forecast, By Application
- 7.4.11.2. Market Size and Forecast, By Indication
- 7.4.11.3. Market Size and Forecast, By Modality
- 7.5.LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Application
- 7.5.3. Market Size and Forecast, By Indication
- 7.5.4. Market Size and Forecast, By Modality
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Nanomedicine Market
- 7.5.6.1. Market Size and Forecast, By Application
- 7.5.6.2. Market Size and Forecast, By Indication
- 7.5.6.3. Market Size and Forecast, By Modality
- 7.5.7. Saudi Arabia Nanomedicine Market
- 7.5.7.1. Market Size and Forecast, By Application
- 7.5.7.2. Market Size and Forecast, By Indication
- 7.5.7.3. Market Size and Forecast, By Modality
- 7.5.8. South Africa Nanomedicine Market
- 7.5.8.1. Market Size and Forecast, By Application
- 7.5.8.2. Market Size and Forecast, By Indication
- 7.5.8.3. Market Size and Forecast, By Modality
- 7.5.9. Rest of LAMEA Nanomedicine Market
- 7.5.9.1. Market Size and Forecast, By Application
- 7.5.9.2. Market Size and Forecast, By Indication
- 7.5.9.3. Market Size and Forecast, By Modality
CHAPTER 8:COMPANY PROFILES
- 8.1. Abbott Laboratories
- 8.1.1.Company Overview
- 8.1.2.Key Executives
- 8.1.3.Company snapshot
- 8.1.4.Operating business segments
- 8.1.5.Product portfolio
- 8.1.6.Business Performance
- 8.1.7.Key Strategic Moves and Developments
- 8.2. DiaSorin S.p.A.
- 8.2.1.Company Overview
- 8.2.2.Key Executives
- 8.2.3.Company snapshot
- 8.2.4.Operating business segments
- 8.2.5.Product portfolio
- 8.2.6.Business Performance
- 8.2.7.Key Strategic Moves and Developments
- 8.3. General Electric Company
- 8.3.1.Company Overview
- 8.3.2.Key Executives
- 8.3.3.Company snapshot
- 8.3.4.Operating business segments
- 8.3.5.Product portfolio
- 8.3.6.Business Performance
- 8.3.7.Key Strategic Moves and Developments
- 8.4. Invitae Corporation
- 8.4.1.Company Overview
- 8.4.2.Key Executives
- 8.4.3.Company snapshot
- 8.4.4.Operating business segments
- 8.4.5.Product portfolio
- 8.4.6.Business Performance
- 8.4.7.Key Strategic Moves and Developments
- 8.5. JOHNSON & JOHNSON
- 8.5.1.Company Overview
- 8.5.2.Key Executives
- 8.5.3.Company snapshot
- 8.5.4.Operating business segments
- 8.5.5.Product portfolio
- 8.5.6.Business Performance
- 8.5.7.Key Strategic Moves and Developments
- 8.6. Leadiant Biosciences, Inc.
- 8.6.1.Company Overview
- 8.6.2.Key Executives
- 8.6.3.Company snapshot
- 8.6.4.Operating business segments
- 8.6.5.Product portfolio
- 8.6.6.Business Performance
- 8.6.7.Key Strategic Moves and Developments
- 8.7. Mallinckrodt Plc
- 8.7.1.Company Overview
- 8.7.2.Key Executives
- 8.7.3.Company snapshot
- 8.7.4.Operating business segments
- 8.7.5.Product portfolio
- 8.7.6.Business Performance
- 8.7.7.Key Strategic Moves and Developments
- 8.8. MERCK & CO., INC.
- 8.8.1.Company Overview
- 8.8.2.Key Executives
- 8.8.3.Company snapshot
- 8.8.4.Operating business segments
- 8.8.5.Product portfolio
- 8.8.6.Business Performance
- 8.8.7.Key Strategic Moves and Developments
- 8.9. PFIZER, INC.
- 8.9.1.Company Overview
- 8.9.2.Key Executives
- 8.9.3.Company snapshot
- 8.9.4.Operating business segments
- 8.9.5.Product portfolio
- 8.9.6.Business Performance
- 8.9.7.Key Strategic Moves and Developments
- 8.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- 8.10.1.Company Overview
- 8.10.2.Key Executives
- 8.10.3.Company snapshot
- 8.10.4.Operating business segments
- 8.10.5.Product portfolio
- 8.10.6.Business Performance
- 8.10.7.Key Strategic Moves and Developments